You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBupranolol
Accession NumberDB08808
TypeSmall Molecule
GroupsApproved
DescriptionBupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to "propranolol":http://www.drugbank.ca/drugs/DB00571.
Structure
Thumb
Synonyms
Bupranol
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BetadrenolDesma
OphtoreninWinzer (Germany)
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Bupranolol hydrochloride
15148-80-8
Thumb
  • InChI Key: WJUUZHQWGKSLIJ-UHFFFAOYSA-N
  • Monoisotopic Mass: 307.1105844
  • Average Mass: 308.24
DBSALT000905
Categories
UNII858YGI5PIT
CAS number14556-46-8
WeightAverage: 271.783
Monoisotopic: 271.13390666
Chemical FormulaC14H22ClNO2
InChI KeyHQIRNZOQPUAHHV-UHFFFAOYSA-N
InChI
InChI=1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3
IUPAC Name
1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol
SMILES
CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1
Pharmacology
IndicationUsed to manage hypertension and tachycardia. Also used to treat glaucoma.
Structured Indications Not Available
PharmacodynamicsBupranolol is a competitive, nonselective beta-blocker similar to propanolol without intrinsic sympathomimetic activity.
Mechanism of actionBupranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinunknown
antagonist
HumanP07550 details
Beta-3 adrenergic receptorProteinunknown
antagonist
HumanP13945 details
Related Articles
AbsorptionQuickly and completely absorbed from the gut with less than 10% oral bioavailability.
Volume of distributionNot Available
Protein binding76%
Metabolism

Over 90% undergo first-pass metabolism. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid, of which 88% are eliminated renally within 24 hours.

SubstrateEnzymesProduct
Bupranolol
Not Available
carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acidDetails
Route of eliminationNot Available
Half life2-4 hours
ClearanceNot Available
ToxicitySymptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bupranolol Action PathwayDrug actionSMP00670
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bupranolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Bupranolol.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Bupranolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Bupranolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bupranolol.Approved
AcetohexamideBupranolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Bupranolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Acetylcholine.Approved
AcetyldigitoxinBupranolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Bupranolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Experimental, Investigational
AlfentanilAlfentanil may increase the bradycardic activities of Bupranolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Bupranolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
AliskirenBupranolol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Bupranolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Bupranolol.Approved
AmbrisentanBupranolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateBupranolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineBupranolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AminophyllineBupranolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Bupranolol.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Bupranolol.Approved
AmobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Bupranolol can be decreased when combined with Amodiaquine.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Bupranolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Bupranolol.Approved
AnvirzelBupranolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
ArbutamineBupranolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Arecoline.Experimental
ArformoterolBupranolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Bupranolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bupranolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Bupranolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
BambuterolBupranolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneThe serum concentration of Bupranolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Barbital.Illicit
BenazeprilBenazepril may increase the hypotensive activities of Bupranolol.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bupranolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Bupranolol.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bupranolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Illicit
BepridilBepridil may increase the hypotensive activities of Bupranolol.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Bupranolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Bupranolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Bupranolol.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Bupranolol.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Bupranolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Bupranolol.Investigational
BosentanBosentan may increase the hypotensive activities of Bupranolol.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Bupranolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Bupranolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Bupranolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Bupranolol.Investigational
BucindololBupranolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bupranolol.Approved, Investigational
CabergolineBupranolol may increase the vasoconstricting activities of Cabergoline.Approved
CandesartanCandesartan may increase the hypotensive activities of Bupranolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Bupranolol.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Bupranolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Bupranolol is combined with Carbachol.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Bupranolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Bupranolol.Approved
CarvedilolBupranolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Bupranolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
CeliprololBupranolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Bupranolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
ChlorpropamideBupranolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bupranolol.Approved
CilazaprilCilazapril may increase the hypotensive activities of Bupranolol.Approved
ClenbuterolBupranolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Bupranolol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Bupranolol.Vet Approved
CryptenamineCryptenamine may increase the hypotensive activities of Bupranolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Bupranolol.Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Bupranolol.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bupranolol.Investigational
DapoxetineThe serum concentration of Bupranolol can be increased when it is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Bupranolol.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Bupranolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Bupranolol.Approved
DeserpidineBupranolol may increase the hypotensive activities of Deserpidine.Approved
DeslanosideBupranolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Bupranolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Bupranolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Bupranolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Bupranolol.Approved
DigitoxinBupranolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinBupranolol may increase the bradycardic activities of Digoxin.Approved
DihydralazineBupranolol may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Bupranolol.Approved
DipivefrinBupranolol may decrease the bronchodilatory activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Bupranolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Bupranolol.Approved
DobutamineBupranolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Bupranolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Bupranolol.Approved
DoxazosinBupranolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Bupranolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Bupranolol.Approved
DroxidopaBupranolol may decrease the bronchodilatory activities of Droxidopa.Approved, Investigational
DuloxetineThe serum concentration of Bupranolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Bupranolol.Investigational
DyphyllineBupranolol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Bupranolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Bupranolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Bupranolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Bupranolol.Approved
EfonidipineBupranolol may increase the hypotensive activities of Efonidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
EnalaprilatBupranolol may increase the hypotensive activities of Enalaprilat.Approved
EphedraBupranolol may decrease the bronchodilatory activities of Ephedra.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Bupranolol is combined with EPIBATIDINE.Experimental
EpinephrineBupranolol may decrease the bronchodilatory activities of Epinephrine.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Bupranolol.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Bupranolol.Approved
EprosartanEprosartan may increase the hypotensive activities of Bupranolol.Approved
Ergoloid mesylateBupranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBupranolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Bupranolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
EtoperidoneThe serum concentration of Bupranolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bupranolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Bupranolol.Investigational
FelodipineFelodipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Bupranolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Bupranolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Bupranolol.Approved
FenoterolBupranolol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylFentanyl may increase the bradycardic activities of Bupranolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Bupranolol.Vet Approved
FingolimodBupranolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bupranolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Bupranolol.Vet Approved
FluoxetineThe serum concentration of Bupranolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Bupranolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
FormoterolBupranolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Bupranolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Bupranolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bupranolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bupranolol.Approved, Nutraceutical
GlibornurideBupranolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideBupranolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBupranolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBupranolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneBupranolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideBupranolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideBupranolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Bupranolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Bupranolol.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Bupranolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
HexamethoniumBupranolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Bupranolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Bupranolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Bupranolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Bupranolol.Approved
HydralazineHydralazine may increase the hypotensive activities of Bupranolol.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Bupranolol.Approved
HydroxychloroquineThe metabolism of Bupranolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Bupranolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Bupranolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Bupranolol.Approved
IloprostIloprost may increase the hypotensive activities of Bupranolol.Approved, Investigational
ImidaprilBupranolol may increase the hypotensive activities of Imidapril.Investigational
IndacaterolBupranolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Bupranolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Bupranolol.Approved
IndenololBupranolol may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinIndomethacin may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Bupranolol.Withdrawn
IndoraminBupranolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkBupranolol may increase the hypoglycemic activities of Insulin Pork.Approved
IproclozideIproclozide may increase the hypotensive activities of Bupranolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Bupranolol.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Bupranolol.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bupranolol.Approved
IsoetarineBupranolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Bupranolol.Approved, Withdrawn
IsoprenalineBupranolol may decrease the bronchodilatory activities of Isoprenaline.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Bupranolol.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Bupranolol.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Bupranolol.Experimental
KetanserinBupranolol may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Bupranolol.Approved
LabetalolBupranolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineBupranolol may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Bupranolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
LevomilnacipranThe serum concentration of Bupranolol can be increased when it is combined with Levomilnacipran.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bupranolol.Approved, Vet Approved
LisinoprilLisinopril may increase the hypotensive activities of Bupranolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Bupranolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
LornoxicamLornoxicam may decrease the antihypertensive activities of Bupranolol.Approved
LosartanLosartan may increase the hypotensive activities of Bupranolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bupranolol.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
MacitentanBupranolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bupranolol.Approved
MalathionMalathion may increase the bradycardic activities of Bupranolol.Approved, Investigational
ManidipineBupranolol may increase the hypotensive activities of Manidipine.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Bupranolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Bupranolol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Bupranolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bupranolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Bupranolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Bupranolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bupranolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Bupranolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bupranolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Bupranolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Bupranolol.Investigational
MethohexitalThe serum concentration of Bupranolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Bupranolol.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Bupranolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bupranolol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
MethylphenobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the hypotensive activities of Bupranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Bupranolol.Approved
MetoprololMetoprolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
MetyrosineBupranolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Bupranolol.Withdrawn
MidodrineBupranolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Bupranolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Bupranolol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Bupranolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Bupranolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Bupranolol.Approved
MoexiprilMoexipril may increase the hypotensive activities of Bupranolol.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Bupranolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Bupranolol.Approved, Withdrawn
MoxonidineBupranolol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bupranolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Bupranolol.Approved
NadololNadolol may increase the hypotensive activities of Bupranolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Bupranolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Bupranolol.Approved
NaftopidilBupranolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Bupranolol.Investigational
NebivololNebivolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
NefazodoneThe serum concentration of Bupranolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Bupranolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Bupranolol.Approved
NialamideNialamide may increase the hypotensive activities of Bupranolol.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Bupranolol.Approved
NicorandilBupranolol may increase the hypotensive activities of Nicorandil.Approved
NicotineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Bupranolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Bupranolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bupranolol.Approved
NiguldipineBupranolol may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Bupranolol.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Bupranolol.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Bupranolol.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Bupranolol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Bupranolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Bupranolol.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Bupranolol.Approved
NorepinephrineBupranolol may decrease the bronchodilatory activities of Norepinephrine.Approved
ObinutuzumabBupranolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Bupranolol.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Bupranolol.Approved, Investigational
OlodaterolBupranolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Bupranolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Bupranolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Bupranolol.Investigational
OrciprenalineBupranolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Bupranolol.Vet Approved
OuabainBupranolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Bupranolol.Approved
OxprenololOxprenolol may increase the hypotensive activities of Bupranolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bupranolol.Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Bupranolol.Approved
PargylinePargyline may increase the hypotensive activities of Bupranolol.Approved
ParoxetineThe serum concentration of Bupranolol can be increased when it is combined with Paroxetine.Approved, Investigational
PenbutololPenbutolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
PentobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Bupranolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bupranolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Bupranolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Bupranolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Bupranolol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Bupranolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Bupranolol.Withdrawn
PhenobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Bupranolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bupranolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Bupranolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
PhenylpropanolamineBupranolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Bupranolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Bupranolol.Withdrawn
PindololPindolol may increase the hypotensive activities of Bupranolol.Approved
PirbuterolBupranolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Bupranolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Bupranolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Bupranolol.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Bupranolol.Approved
PrazosinBupranolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Bupranolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Bupranolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaterolBupranolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
PromazinePromazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Bupranolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Bupranolol.Approved
PropafenoneThe serum concentration of Bupranolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Bupranolol.Vet Approved
PropranololPropranolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Bupranolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Bupranolol.Approved
QuinaprilQuinapril may increase the hypotensive activities of Bupranolol.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Bupranolol.Approved
RamiprilRamipril may increase the hypotensive activities of Bupranolol.Approved
RasagilineRasagiline may increase the hypotensive activities of Bupranolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Bupranolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Bupranolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Bupranolol.Approved
RescinnamineBupranolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Bupranolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Bupranolol.Experimental, Investigational
RifampicinThe serum concentration of Bupranolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bupranolol can be decreased when it is combined with Rifapentine.Approved
RilmenidineBupranolol may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatBupranolol may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
RitodrineBupranolol may decrease the bronchodilatory activities of Ritodrine.Approved
RituximabBupranolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Bupranolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Bupranolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Bupranolol.Withdrawn
SalbutamolBupranolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Bupranolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
SalmeterolBupranolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Bupranolol.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Bupranolol.Experimental
SecobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Bupranolol.Approved, Investigational, Vet Approved
SelexipagBupranolol may increase the hypotensive activities of Selexipag.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
SertralineThe serum concentration of Bupranolol can be increased when it is combined with Sertraline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Bupranolol.Approved, Investigational
SilodosinBupranolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanBupranolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSpirapril may increase the hypotensive activities of Bupranolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Bupranolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Bupranolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bupranolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Bupranolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Bupranolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Bupranolol.Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Bupranolol.Approved, Investigational
TamsulosinBupranolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Bupranolol.Approved, Investigational
TemocaprilBupranolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Bupranolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Bupranolol.Vet Approved
TerazosinBupranolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineBupranolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bupranolol.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Bupranolol.Approved, Investigational
TheophyllineBupranolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThe serum concentration of Bupranolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bupranolol.Withdrawn
ThiopentalThe serum concentration of Bupranolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Bupranolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bupranolol.Approved
TiboloneBupranolol may increase the hypotensive activities of Tibolone.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Bupranolol.Withdrawn
TimololTimolol may increase the hypotensive activities of Bupranolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Bupranolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
TolazamideBupranolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
TolbutamideBupranolol may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bupranolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Bupranolol.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Bupranolol.Approved
TorasemideTorasemide may increase the hypotensive activities of Bupranolol.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Bupranolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bupranolol.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Bupranolol.Approved
TravoprostTravoprost may increase the hypotensive activities of Bupranolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Bupranolol.Approved, Investigational
TrichlorfonTrichlorfon may increase the bradycardic activities of Bupranolol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bupranolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
TrimazosinBupranolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Bupranolol.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Bupranolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Bupranolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Bupranolol.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Bupranolol.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bupranolol.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Bupranolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Bupranolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Bupranolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Bupranolol.Approved
VilanterolBupranolol may decrease the bronchodilatory activities of Vilanterol.Approved
VinpocetineBupranolol may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bupranolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Bupranolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Bupranolol.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Kunz, W., Jacobi, H., Koch, C. and Geus, R.J.; U.S. Patent 3,309,406; March 14, 1967.

General ReferencesNot Available
External Links
ATC CodesC07AA19
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9784
Blood Brain Barrier-0.7572
Caco-2 permeable+0.5576
P-glycoprotein substrateSubstrate0.6384
P-glycoprotein inhibitor INon-inhibitor0.6857
P-glycoprotein inhibitor IINon-inhibitor0.8993
Renal organic cation transporterNon-inhibitor0.8713
CYP450 2C9 substrateNon-substrate0.8011
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6373
CYP450 1A2 substrateInhibitor0.5416
CYP450 2C9 inhibitorNon-inhibitor0.8165
CYP450 2D6 inhibitorInhibitor0.6045
CYP450 2C19 inhibitorNon-inhibitor0.7218
CYP450 3A4 inhibitorNon-inhibitor0.8424
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5726
Ames testNon AMES toxic0.9025
CarcinogenicityNon-carcinogens0.8249
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4441 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Non-inhibitor0.6443
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.143 mg/mLALOGPS
logP3.14ALOGPS
logP2.99ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area41.49 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity74.86 m3·mol-1ChemAxon
Polarizability30.35 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Zelaszczyk D, Kozlowska H, Baranowska U, Baranowska M, Reutelsterz A, Kiec-Kononowicz K, Malinowska B, Schlicker E: Four close bupranolol analogues are antagonists at the low-affinity state of beta1-adrenoceptors. J Physiol Pharmacol. 2009 Mar;60(1):51-60. [PubMed:19439807 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Lenard NR, Gettys TW, Dunn AJ: Activation of beta2- and beta3-adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther. 2003 May;305(2):653-9. Epub 2003 Jan 24. [PubMed:12606631 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name:
ADRB3
Uniprot ID:
P13945
Molecular Weight:
43518.615 Da
References
  1. Lenard NR, Gettys TW, Dunn AJ: Activation of beta2- and beta3-adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther. 2003 May;305(2):653-9. Epub 2003 Jan 24. [PubMed:12606631 ]
  2. Matsushita M, Horinouchi T, Tanaka Y, Tsuru H, Koike K: Characterization of beta 3-adrenoceptor-mediated relaxation in rat abdominal aorta smooth muscle. Eur J Pharmacol. 2003 Dec 15;482(1-3):235-44. [PubMed:14660028 ]
Comments
comments powered by Disqus
Drug created on October 20, 2010 15:45 / Updated on August 17, 2016 12:24